Mixed Results for Baricitinib in Trial of Hospitalized COVID-19 Patients
Findings showed that the trial did not meet statistical significance on the primary endpoint.
Findings showed that the trial did not meet statistical significance on the primary endpoint.
Wyoming’s 36.7 percent increase since last week in its rolling seven-week average was the largest of any state
Sisunatovir is an orally administered RSV fusion inhibitor that binds to RSV-F protein on the viral surface inhibiting RSV replication.
Dose-response relationship observed; risk up 3.67-fold for those using PPIs up to twice daily.
This week on the pod we look at results from a COVID-19 prevention trial of hydroxychloroquine; A vaccine arrival date prediction by Dr Fauci; A FDA notification regarding vial caps; A look into prescription patterns during COVID-19; And an antibody treatment trial begins.
Evidence presented for delirium during COVID-19, post-illness neuropsychiatric consequences for SARS, MERS
An investigational vaccine to protect against respiratory syncytial virus (RSV) infection has received Fast Track designation from the Food and Drug Administration (FDA).
Vanco Ready, a ready-to-use (RTU) vancomycin injection, has been made available by Xellia Pharmaceuticals. The new 100mL premixed bag contains 500mg of vancomycin and is stable at room temperature (up to 25 °C) with a 16-month shelf life in overwrap and 28-day shelf life outside of overwrap. The product can also be stored in automated…
Findings observed for acute respiratory infection in emergency departments and urgent care centers
However, most pertussis cases occur among vaccinated children further away from last DTaP dose